"Z(MZE0002716202)" . "Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100 mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models."@en . "5" . . . . "Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect" . "8"^^ . "Korvasov\u00E1, Zina" . . "[836C411E3817]" . . . "Ma\u0161ek, Josef" . . "99" . . "8"^^ . "Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect" . "0022-3549" . . "Tur\u00E1nek, Jaroslav" . . "Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect"@en . "11"^^ . "RIV/00027162:_____/10:#0000612!RIV11-MZE-00027162" . . . . . . "000277132500009" . . . . "Plockov\u00E1, Jana" . . . . . . . "\u0160krabalov\u00E1, Michaela" . "Tur\u00E1nek-Kn\u00F6tigov\u00E1, Pavl\u00EDna" . . . . "RIV/00027162:_____/10:#0000612" . "Journal of Pharmaceutical Sciences" . . "Koudelka, \u0160t\u011Bp\u00E1n" . "268613" . "Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100 mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect"@en . . "B16F10; extrusion; hollow fibre implants; liposomes; lyophilisation; melanoma; nanotechnology; paclitaxel; particle size; stability"@en . "Bartheldyov\u00E1, Eli\u0161ka" .